Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01796197
Title Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Cyclophosphamide + Doxorubicin

Pertuzumab + Trastuzumab

Paclitaxel

Age Groups: adult
Covered Countries USA


No variant requirements are available.